Avanos Medical, Inc.
AVNS · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $1 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 1.6% | 4.5% | -6.7% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 45.6% | 52.6% | 53.6% | 55.3% |
| EBITDA | $0 | -$0 | $0 | -$0 |
| % Margin | 5.6% | -36.5% | 12.8% | -226.4% |
| Net Income | -$0 | -$0 | $0 | -$0 |
| % Margin | -0.8% | -43.9% | 3.9% | -221.2% |
| EPS Diluted | -0.03 | -1.66 | 0.14 | -8.64 |
| % Growth | 98.2% | -1,285.7% | 101.6% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | -$0 | $0 | $0 |